Dermatology News and Research

Latest Dermatology News and Research

RXi Pharmaceuticals, TransDerm collaborate on study of RXi's proprietary compounds in dermatology applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), and TransDerm, Inc., a biopharmaceutical company developing nucleic acid skin delivery technologies and therapeutics for skin disorders, announced today that they will collaborate on studying the potential utility of RXi's proprietary compounds in dermatology models.

7 Apr 2010

DLVSC offers Zeltiq procedure to freeze away unwanted fat cells

Zeltiq™, an innovative technology that freezes away unwanted fat, is now available at Dermatology, Laser and Vein Specialists of the Carolinas – making DLVSC one of the first medical practices in the Southeast to offer this breakthrough in fat reduction.

6 Apr 2010

First Edition: April 6, 2010

Among today's headlines is news about a lawsuit filed by Massachusetts insurers who are seeking to reverse the state insurance commissioner's decision and allow them to raise rates.

6 Apr 2010

OMA calls for restrictions on the use of artificial tanning equipment

Ontario's doctors are moving to dispel the common misconception that salon tanning beds are safer than the sun. Recently, the Ontario Medical Association adopted a policy calling for restrictions on the use of artificial tanning equipment, so that tanning beds cannot be used by those under 18 years of age.

6 Apr 2010

Halozyme Therapeutics secures multiple commercial supply agreements for rHuPH20

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC.

5 Apr 2010

Warner Chilcott, sanofi-aventis amend Actonel global collaboration agreement

Warner Chilcott plc and sanofi-aventis announced today an amendment to the Actonel® global collaboration agreement with respect to the parties' arrangement in the United States and Puerto Rico. Under the terms of the amendment, Warner Chilcott will take full operational control over the promotion, marketing and R&D decisions for Actonel in the United States and Puerto Rico, and will assume responsibility for all associated costs relating to those activities.

5 Apr 2010

Donate Life America survey reveals pervasive donation myths

According to a new survey by Donate Life America, 43 percent of people are undecided, reluctant or do not wish to have their organs and tissue donated after their deaths. While an improvement over findings from a similar survey last year in which 50 percent reported the same, the statistic illustrates a critical need to continue to increase the level of support for organ donation to save the lives of the more than 105,000 adults and children on the transplant waiting list in the U.S., an average 18 of whom die each day waiting.

5 Apr 2010

EvoLife Laboratories introduces cancer care products in USA

EvoLife Laboratories, a world leader in the development of products for skin, oral, nail, hair, hygiene care specifically designed for cancer patients undergoing chemotherapy and radiotherapy, announced the launch of its products in USA.

31 Mar 2010

NovaBay Pharmaceuticals reports net income of $2.7M for 2009 against year-ago loss

NovaBay Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported full-year and fourth quarter financial results for 2009. The company also highlighted recent progress of its proprietary and partnered development programs.

30 Mar 2010

LeAnn Rimes encourages psoriasis patients to take Make a Change Pledge

Grammy Award-winning multi-platinum recording artist and psoriasis patient LeAnn Rimes is calling for people with psoriasis to pledge to better manage their disease as part of the awareness campaign "Stop Hiding from Psoriasis." In partnership with the American Academy of Dermatology and National Psoriasis Foundation, LeAnn is encouraging people to take a stand against psoriasis by taking the Make a Change Pledge online at StopHiding.org.

30 Mar 2010

Strong lobbying efforts by tanning bed industry a barrier to passage of legislation

Researchers from Boston University School of Medicine (BUSM) have found that when attempting to pass tanning bed legislation, successful advocates collaborate with local and national organizations and lobbyists and have direct contact with the sponsoring legislator to aid in the passage of the bill. These findings, which appear on-line in the Journal of the American Academy of Dermatology, also identify strong lobbying efforts by the tanning bed industry as the biggest barrier to passing tanning bed legislation.

27 Mar 2010

Biophotonics: Light to cure disease

Biophotonics, or photomedicine, is a relatively unknown discipline, though it has existed for years now. You may have even benefited from it without realizing it. Some of the greatest advances of this field can be found in applications for the areas of oncology, dermatology, ophthalmology, surgery and cardiology.

27 Mar 2010

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

American Academy of Dermatology Association (AADA) President and dermatologist William D. James, MD, FAAD, along with other dermatologists and leading researchers today testified before a Food and Drug Administration (FDA) panel considering changes to the current classification of indoor tanning devices. Currently, the FDA classifies indoor tanning devices as Class 1, the category for items that have minimal potential to cause harm to individuals. Items in Class 1 include adhesive bandages and tongue depressors.

27 Mar 2010

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Graceway® Pharmaceuticals announced today that the Food and Drug Administration has approved the New Drug Application for Zyclara™, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

27 Mar 2010

Oculus Innovative Sciences introduces Microcyn Dermatology HydroGel in the U.S.

Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today commercially introduced the Microcyn Dermatology HydroGel for the U.S. professional healthcare market.

26 Mar 2010

Isotechnika Pharma releases fourth quarter financial results; reviews operational and scientific highlights for 2009

Isotechnika Pharma Inc. has released its financial results for the fourth quarter and year ended December 31, 2009 and provided a review of the Company's operational and scientific highlights for 2009

25 Mar 2010

Skinvisible obtains Korean patent for polymer delivery system

Skinvisible, Inc. announced today that the South Korean patent office has granted a patent for Invisicare®, the company's polymer delivery system for topical dermatology products.

24 Mar 2010

New provision in health care bill ensures physicians’ participation in PQRI program

A provision in the health care reform measure passed by the House of Representatives Sunday and signed into law today by President Barack Obama includes participation in the American Board of Medical Specialties Maintenance of Certification® (ABMS MOC®) as an option for the nation’s physicians to fulfill requirements of the Centers for Medicare and Medicaid Services (CMS) Physician Quality Reporting Initiative (PQRI

24 Mar 2010

Medx Health acquires Canadian operations of Reimers & Janssen GmbH

MedX Health Corp., a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced it has acquired the Canadian operations of 27 year old laser pioneer, Reimers & Janssen GmbH (herein after "RJ-Laser"), providing an expanded line of products, with improved product features, within MedX's existing rehab/chiropractic, dental, and acupuncture laser and light markets, as well as approved products ready for launch to Veterinarians and Dermatologists.

23 Mar 2010

Garnet BioTherapeutics commences treatment in GBT009 trial for incisional wounds following breast reconstruction surgery

Garnet BioTherapeutics, Inc., a regenerative medicine company focused on developing cell based therapies, today announced that the first patient has been treated in a Phase 2 multicenter, double-blind, placebo-controlled study of its lead product candidate GBT009 at Unity Hospital in Rochester, New York. GBT009 gives off a variety of pro-regenerative growth factors and cytokines which help repair damaged tissue and reduce inflammation, ultimately augmenting the body's ability to heal itself.

23 Mar 2010